Eton Pharmaceuticals Acquires U.S. Rights to HEMANGEOL

Eton Pharmaceuticals ( (ETON) ) has shared an announcement.

On February 27, 2026, Eton Pharmaceuticals entered a licensing agreement to acquire the U.S. rights to HEMANGEOL, the only FDA-approved propranolol oral solution for infantile hemangioma requiring systemic therapy, from Pierre Fabre Medicament. The transaction, announced on March 2, 2026, adds an orphan drug with an estimated 5,000–10,000 treated U.S. infants annually and is expected to be accretive to Eton’s 2026 earnings, consolidating Pierre Fabre’s global commercialization role while transferring U.S. marketing to Eton from May 1.

HEMANGEOL will be sold through the company’s Eton Cares patient support program, which offers prescription fulfillment, insurance navigation, educational support and a $0 co-pay for qualifying patients to broaden access to this critical pediatric therapy. Combined with the recent approval of DESMODA, the deal allows Eton to reach a milestone of ten commercial rare disease products, reinforcing its ambition to build one of the largest rare disease portfolios in the U.S. and deepening its position in pediatric specialty markets.

The most recent analyst rating on (ETON) stock is a Buy with a $37.00 price target. To see the full list of analyst forecasts on Eton Pharmaceuticals stock, see the ETON Stock Forecast page.

Spark’s Take on ETON Stock

According to Spark, TipRanks’ AI Analyst, ETON is a Neutral.

ETON scores as moderately attractive primarily due to improving fundamentals—strong revenue acceleration, robust operating/free cash flow, and a de-risked balance sheet—supported by a generally positive earnings-call outlook on growth and margins. The score is held back by weak technical trends and the lack of current profitability (negative earnings and net losses), with valuation less supportive due to negative EPS and no dividend yield.

To see Spark’s full report on ETON stock, click here.

More about Eton Pharmaceuticals

Eton Pharmaceuticals, Inc. is a U.S.-based innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The company now markets ten commercial rare disease products, including KHINDIVI, INCRELEX, ALKINDI SPRINKLE, DESMODA, GALZIN, HEMANGEOL, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone, and has four additional late-stage candidates in its pipeline.

The company’s strategy centers on building one of the largest rare disease portfolios in the United States, targeting niche patient populations with high unmet medical need. Its commercial model emphasizes specialty distribution and patient support services, including the Eton Cares program, to improve treatment access and adherence for complex, often pediatric, conditions.

Average Trading Volume: 250,273

Technical Sentiment Signal: Strong Buy

Current Market Cap: $455.6M

See more data about ETON stock on TipRanks’ Stock Analysis page.